Unknown

Dataset Information

0

Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells.


ABSTRACT:

Purpose

Postmenopausal women with estrogen receptor-positive breast cancers often respond initially to tamoxifen or aromatase inhibitor therapy. Resistance to these treatments usually develops within 12 to 18 months. Clinical studies have demonstrated that high-dose estrogen can induce regression of these endocrine-resistant tumors. However, side-effects of high-dose estradiol (E2) or diethylstilbestrol (DES) limit their usage. Estetrol (E4) is the most abundant estrogen during pregnancy and has a long half-life and a low potential for side-effects. Estetrol might then provide benefits similar to DES on tumor regression but with lesser toxicity.

Methods

In this study, we systematically evaluated the effects of E4 on cell proliferation and apoptosis in wild-type MCF-7 and long-term estrogen-deprived (LTED) MCF-7 cells and compared its effects with E2 and estriol (E3).

Results

Estetrol induced apoptosis in LTED cells but stimulated growth of MCF-7 cells at concentrations from 10-11 to 10-8 M. These effects of E4 are similar to those of E2 but require much higher doses. Differing from E2, E4 at 10-12 M induced apoptosis in MCF-7 cells and another pregnancy estrogen, E3, acted similarly. No antagonistic effect of E4 or E3 against E2 occurred when they were combined.

Conclusions

The pro-apoptotic effects of E4 and E3 on LTED cells and at low doses on MCF-7 cells indicate that these steroids could be used as therapeutic agents for endocrine-resistant or sensitive breast cancer.

SUBMITTER: Yue W 

PROVIDER: S-EPMC6535901 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pro-Apoptotic Effects of Estetrol on Long-Term Estrogen-Deprived Breast Cancer Cells and at Low Doses on Hormone-Sensitive Cells.

Yue Wei W   Verhoeven Carole C   Bernnink Herjan Coelingh HC   Wang Ji-Ping JP   Santen Richard J RJ  

Breast cancer : basic and clinical research 20190515


<h4>Purpose</h4>Postmenopausal women with estrogen receptor-positive breast cancers often respond initially to tamoxifen or aromatase inhibitor therapy. Resistance to these treatments usually develops within 12 to 18 months. Clinical studies have demonstrated that high-dose estrogen can induce regression of these endocrine-resistant tumors. However, side-effects of high-dose estradiol (E<sub>2</sub>) or diethylstilbestrol (DES) limit their usage. Estetrol (E<sub>4</sub>) is the most abundant est  ...[more]

Similar Datasets

| S-EPMC10527823 | biostudies-literature
| S-EPMC8960923 | biostudies-literature
| S-ECPF-GEOD-10879 | biostudies-other
| S-EPMC6515029 | biostudies-literature
| S-EPMC3715569 | biostudies-literature
| S-EPMC7788918 | biostudies-literature
| S-EPMC6279501 | biostudies-literature
| S-EPMC6774891 | biostudies-literature
| S-EPMC5845891 | biostudies-literature
| S-ECPF-GEOD-59535 | biostudies-other